GlassScriptPhysician profile
Ramakrishna Kanuri
NPI 1487615712
$3,609.34
in general payments reported to CMS, 2019-2025
10 companies · $913 in 2025
The $913 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $82.02 · 2021: $174 · 2022: $206 · 2023: $311 · 2024: $1,651 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,842 · Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,842.44 |
| Food and Beverage | $1,032.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,220.58 | 2022-2025 | Gi Genius, Endoflip |
| Intercept Pharmaceuticals, INC. | $329.34 | 2019-2023 | Ocaliva |
| Abbvie INC. | $299.12 | 2019-2024 | |
| Janssen Biotech, INC. | $150.00 | 2024 | Tremfya, Stelara |
| Gilead Sciences, INC. | $134.80 | 2019-2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $126.01 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $121.36 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $115.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.53 | 2021 | |
| Intra-Sana Laboratories | $20.15 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramakrishna Kanuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.